Peptide Knowledge Base · Cognition

PE-22-28: what it is, what the evidence says, and its real status

A preclinical mood peptide built around a fast-antidepressant mechanism (TREK-1 blockade). Interesting target, no human data.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does PE-22-28 work?

A spadin-derived peptide that blocks the TREK-1 potassium channel, a target linked to fast-acting antidepressant effects in animal models.

What it does — and what it does not do

What it does: Showed antidepressant-like effects in animal studies.

What it does not do: It has no human data, is not approved, and is not a treatment for depression or any mood condition.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

preclinical only; no human data

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: No human safety or efficacy data; durability of the antidepressant effect is unknown.

WADA status: Not prohibited.

Who should not take it

No human characterization; not a substitute for evaluation/treatment of a mood disorder.

Sources

Spadin / PE-22-28 TREK-1 antidepressant preclinical literature

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.